What question did this study set out to answer?

This study aims to evaluate the effects of isorhamnetin on ovarian cell viability and hormone secretion.

August 1, 2026PharmaceuticalsOpen Access

Isorhamnetin and Female Reproduction: Effects on Viability, Hormone Secretion, and Growth Factors

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates isorhamnetin's effects on ovarian cell viability, suggesting potential cancer therapy.

This study aims to evaluate the effects of isorhamnetin on ovarian cell viability and hormone secretion.
Human granulosa, granulosa tumor, and epithelial ovarian carcinoma cell lines were treated with isorhamnetin.
Cell viability was measured using the AlamarBlue assay.
Hormone and growth factor levels were quantified using enzyme-linked immunosorbent assay (ELISA).
Isorhamnetin reduced cell viability in a dose-dependent manner, with significant effects in OVCAR-3 from 10 μg/mL.
COV434 cells showed significant viability reductions at 20 μg/mL and higher.
Limited effects on steroid hormone secretion and growth factors were noted, with significant AIF reductions in HGL5 only at 80 μg/mL.

Mihaľ et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark